PRESS RELEASE : Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth

DGAP-News: Imcyse SA / Key word(s): Miscellaneous 
Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth 
2021-06-24 / 14:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth 
- Appointment of new Scientific Advisory Board comprising thought leaders from academia and industry to boost pipeline 
progress and expansion 
- New laboratories will accommodate growing team and increased activities 
- Move supported by key shareholder Noshaq and SPI and confirms Imcyse's commitment to the Walloon Region of Belgium, a 
leading center for talent and R&D within Europe 
Liège, Belgium, June 24, 2021 - Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new 
class of active and specific immunotherapies for the treatment of severe autoimmune diseases, is pleased to announce 
the formation of a Scientific Advisory Board ("SAB") and the opening of its new office and laboratory. These 
developments will enable the next phase of growth in the Walloon region's diverse and innovative scientific and 
academic ecosystems. 
During the past year, Imcyse has achieved significant milestones with the start of the company's Phase 2b study in T1D, 
a research and collaboration agreement with Pfizer in Rheumatoid Arthritis and a financing round raising an additional 
EUR21m. To help enable the expansion of its Imotope^TM platform to new indications and therapeutic areas, Imcyse has now 
strengthened and expanded its Scientific Advisory Board with thought leaders from academia and industry. The new SAB 
comprises of eight leading international experts spanning the fields of Immunology, Inflammation, Vaccinology, Oncology 
and Autoimmune Disease and will consult with Imcyse's leadership team and provide independent scientific review and 
advice. The diverse experience from both the EU and US will help the company identify new opportunities, optimize 
current research, and help guide the preparation for the next and decisive steps in the expansion of its development 
programs in indications such as T1D, Multiple Sclerosis, Rheumatoid Arthritis, Neuromyelitis Optica and Celiac Disease. 
"Autoimmune disorders cause a wide range of debilitating and chronic impairments which makes the clincial management 
challenging and constitutes a burden for patients and society. While symptomatic treatments are available, definitive 
cures have yet to be approved. Imcyse's novel approach has the potential to pave the way for a new class of therapies 
which specifically block disease pathways and could provide long term treatment benefits for patients and could 
possibly cure patients with a safe and convenient treatment," said Prof. Mark Anderson, M.D., Ph.D., Professor in the 
UCSF Diabetes Research Center in San Francisco, USA, and member of the newly formed Advisory Board of Imcyse. "I am 
excited to be part of the Imcyse's Scientific Advisory Board and am looking forward to working with the management team 
and alongside my fellow Advisory Board members, each remarkable experts in their field, to support Imcyse in its 
efforts to further the development of Imotopes in its current indications and identify novel targets where this 
technology could make a significant difference." 
To accommodate the strong growth both in the company's scientific team as well as in the number of pipeline programs, 
Imcyse has relocated its headquarters. The new premises feature purpose built and equipped laboratories tailored to the 
unique requirements of Imcyse's technology. This enables its specialist research and will allow for future growth in 
one location, enhancing collaboration and productivity among employees and drive efficiency and innovation for the 
company. 
The move was made possible thanks to the tremendous support of Noshaq Immo, Noshaq Group property division, and SPI, 
the development agency of the Province of Liège. 
"The new headquarters and SAB are milestones of our long-term focus and reflect our strategic vision making a 
significant impact on the treatment of severe autoimmune diseases which have high unmet needs for new medicines. We are 
proud to have gathered such a renowned Scientific Advisory Board to support our future development plans for our unique 
proprietary Imotope^TM platform. I am certain, that they will play a key role, alongside our team, in developing and 
guiding our scientific agenda," said Denis Bedoret, Imcyse CEO. "We are grateful for the fundamental support from the 
Walloon Region with its mix of academia and industry to which we have very strong ties and are pleased to continue to 
be an active part. I am excited about the team we have built to continue advance our Imotope(TM) platform which could 
stop severe autoimmune diseases from progressing. Our new office and laboratory facilities, supported by our key 
shareholder Noshaq and SPI will provide the special facilities and equipment to allow us to make our vision a reality." 
"A successful collaboration as well as a good example of the global and tailor-made support that Noshaq Immo is able to 
offer, both from a real estate and a funding point of view," underscored Frédéric Driessens, Managing Director at 
Noshaq Immo. "We were glad to help Imcyse go through the different steps of developing and funding their new 
headquarters. It is the perfect illustration of the kind of support we can provide to pioneering life science companies 
such as Imcyse." 
Imotope^TM platform to prevent, stop and potentially cure autoimmune diseases 
The Imcyse Imotope^TM platform represents a next generation and potentially curative approach to severe autoimmune 
diseases for which there is no satisfactory therapy. Imotopes^TM induce cytolytic CD4+ T cells, which specifically 
eliminate the aberrant disease pathway while leaving the rest of the immune system unaffected. In addition to the Type 
1 Diabetes program, its Multiple Sclerosis candidate is expected to commence clinical trials in 2022. In RA, Pfizer and 
Imcyse will collaborate to develop existing lead candidates and further optimize potential molecules. After a candidate 
is selected, Pfizer will lead clinical development and commercialisation activities. 
Composition of the Imcyse Scientific Advisory Board: 
Prof. Eva M Martinez-Caceres, M.D., Ph.D. 
Head of the Immunology Division and Associate Professor of Immunology at the Autonomous University Barcelona (Spain) 
Prof. Chantal Mathieu, M.D., Ph.D. 
Chair of Endocrinology at University Hospital Gasthuisberg, Leuven and Chair European Diabetes Forum (Belgium) 
Dr. Marcelle Van Mechelen, Ph.D. 
Independent senior scientific advisor in the fields of vaccine, autoimmunity, oncology and regenerative medicine 
(Belgium) 
Prof. Mark Anderson, M.D., Ph.D. 
Professor in the UCSF Diabetes Center (San Francisco, USA) 
Prof. Bart N. Lambrecht, M.D., Ph.D. 
Professor of Pulmonary Medicine at Erasmus MC and at UGent, and director of the VIB Inflammation Research (Belgium) 
Dr. Adrian Liston, Ph.D. 
Senior Group Leader at the Babraham Institute (Cambridge, UK) 
Prof. Patrick Vermersch, M.D., Ph.D. 
Vice-president for research in biology and health at the University of Lille (France) 
Dr. Michael Vincent, M.D., Ph.D. 
Senior Vice President and CSO of Inflammation and Immunology at Pfizer (USA) 
For more information on the Imcyse Scientific Advisory Board, please visit: https://www.imcyse.com/about-us/ 
scientific-advisory-board.html. 
### 
ABOUT IMCYSE 
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active and specific 
immunotherapies for the treatment of severe autoimmune diseases. The company's unique technology platform allows it to 
specifically target immune cells involved in the destruction of the diseased organ. Disease specific Imotopes(TM), 
which are modified peptides, generate cytolytic CD4+ T-cells, that eliminate antigen-presenting cells and autoantigen 
specific lymphocytes. The Imotope(TM) effect, sustained over time, helps to prevent and treat diseases with no current 
curative alternative and to potentially cure patients without causing generalized immune suppression. The company has 
established proof of concept in several indications and has started a Phase 2 clinical program in type 1 diabetes with 
promising results already seen during the first Phase 1 trial. Beyond type 1 diabetes, Imcyse is developing a pipeline 
of Imotopes(TM) for the treatment of several autoimmune diseases. Founded as a spin-off of the Catholic University of 
Leuven Imcyse subsequently relocated to Liège, Belgium. 
www.imcyse.com 
CONTACT:                 FOR MEDIA INQUIRES: 
Imcyse S.A.              MC Services AG 
Denis Bedoret            Anne Hennecke / Julia Bittner 
Chief Executive Officer  Mail: [e-mail] 
Mail: [e-mail] Tel.: [phone] ----------------------------------------------------------------------------------------------------------------------- 

2021-06-24 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

1211691 2021-06-24

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1211691&application_name=news

(END) Dow Jones Newswires

June 24, 2021 08:00 ET (12:00 GMT)